Evaluation and Management of Obesity¶
Chapter 414 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Obesity is a heterogeneous condition with strong associations to metabolic syndrome, type 2 diabetes, cardiovascular disease, and various cancers.
- Lifestyle modification remains the cornerstone of obesity management, with pharmacotherapy and bariatric surgery reserved for severe cases.
- BMI classification and waist circumference are critical for staging obesity severity and assessing comorbid risks.
1. DEFINITION & OVERVIEW¶
Obesity is a medical disorder characterized by excessive fat accumulation, leading to adverse health outcomes. It is strongly linked to metabolic, cardiovascular, and oncologic complications. The condition is heterogeneous, with genetic, environmental, and behavioral factors contributing to its pathogenesis.
Table 414-1: Classification of Weight Status and Disease Risk¶
| CLASSIFICATION | BODY MASS INDEX (kg/m²) | OBESITY CLASS | DISEASE RISK |
|---|---|---|---|
| Underweight | <18.5 | — | — |
| Healthy weight | 18.5–24.9 | — | — |
| Overweight | 25.0–29.9 | — | Increased |
| Obesity | 30.0–34.9 | I | High |
| Obesity | 35.0–39.9 | II | Very high |
| Obesity | ‡40 | III | Extremely high |
1.1 Obesity-Related Complications¶
Obesity is associated with hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, nonalcoholic steatohepatitis (NASH), and increased cancer risk (e.g., colorectal, endometrial, and esophageal adenocarcinoma).
1.2 Role of Lifestyle and Comorbidities¶
Insulin resistance and hormonal imbalances (e.g., leptin, ghrelin) drive metabolic dysfunction. Obesity also exacerbates cardiovascular risk and contributes to musculoskeletal disorders like osteoarthritis.
2. EPIDEMIOLOGY¶
Obesity prevalence has risen globally, with over 70% of U.S. adults classified as overweight or obese. Risk factors include genetic predisposition, sedentary lifestyle, poor diet, and environmental influences. Ethnic-specific waist circumference thresholds (e.g., >94 cm for European men) are critical for risk stratification.
Table 414-2: Ethnic-Specific Waist Circumference Cutpoints¶
| ETHNIC GROUP | WAIST CIRCUMFERENCE |
|---|---|
| Europeans | Men >94 cm (>37 in), Women >80 cm (>31.5 in) |
| South Asians/Chinese | Men >90 cm (>35 in), Women >80 cm (>31.5 in) |
| Japanese | Men >85 cm (>33.5 in), Women >90 cm (>35 in) |
| Ethnic South and Central Americans | Use South Asian recommendations |
| Sub-Saharan Africans | Use European data |
| Eastern Mediterranean/Middle Eastern | Use European data |
2.1 Demographics¶
Rates are increasing in adolescents and adults, with higher prevalence in developed countries. Ethnic disparities exist, necessitating tailored cutpoints for waist circumference (e.g., South Asians >90 cm).
2.2 Comorbidities¶
Obesity is a major risk factor for cardiovascular disease, type 2 diabetes, and certain cancers. The risk of mortality from obesity-related cancers (e.g., esophageal adenocarcinoma) has increased with rising BMI.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Obesity results from energy imbalance, with genetic, hormonal, and environmental factors contributing. Insulin resistance, leptin resistance, and dysregulated ghrelin signaling drive metabolic dysfunction. Central obesity exacerbates visceral fat accumulation, leading to systemic inflammation and organ-specific complications.
3.1 Hormonal and Metabolic Mechanisms¶
Insulin resistance, hyperinsulinemia, and dysregulated adipokines (e.g., adiponectin, interleukin-6) contribute to metabolic syndrome. Leptin resistance impairs satiety signals, while ghrelin promotes hunger.
3.2 Genetic and Environmental Factors¶
Genetic variants (e.g., FTO) predispose to obesity, but environmental factors like diet and physical activity play a dominant role. Epigenetic modifications may also influence fat distribution and metabolic risk.
4. CLINICAL FEATURES¶
Clinical manifestations include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, and musculoskeletal pain. Skin complications (e.g., acanthosis nigricans, hidradenitis suppurativa) and psychosocial issues (e.g., depression, stigma) are also common.
Table 414-3: Obesity-Related Organ Systems Review¶
| ORGAN SYSTEM | CLINICAL FEATURES |
|---|---|
| Cardiovascular | Hypertension, congestive heart failure, cor pulmonale |
| Respiratory | Obstructive sleep apnea, hypoventilation syndrome |
| Gastrointestinal | Gastroesophageal reflux, cholelithiasis |
| Endocrine | Polycystic ovarian syndrome, hypogonadism |
| Musculoskeletal | Osteoarthritis, gout |
| Psychological | Depression, body image disturbance |
4.1 Organ-Specific Complications¶
Cardiovascular: Hypertension, coronary artery disease. Respiratory: Sleep apnea. Gastrointestinal: Gastroesophageal reflux, gallstones. Endocrine: Polycystic ovary syndrome, hypogonadism.
4.2 Psychosocial Impact¶
Obesity is linked to depression, low self-esteem, and social stigma. These factors exacerbate obesity through stress-induced eating and reduced physical activity.
5. DIFFERENTIAL DIAGNOSIS¶
Secondary causes of obesity include endocrine disorders (e.g., Cushing’s syndrome, hypothyroidism), medications (e.g., corticosteroids, antipsychotics), and genetic syndromes (e.g., Prader-Willi, Bardet-Biedl). These must be excluded in patients with rapid weight gain or atypical presentations.
5.1 Endocrine Disorders¶
Cushing’s syndrome, hypothyroidism, and hypercortisolism can mimic obesity. Laboratory tests for cortisol, thyroid function, and ACTH are critical.
5.2 Medication-Induced Weight Gain¶
Drugs like insulin, antipsychotics, and anticonvulsants (e.g., valproate) can cause weight gain. Discontinuation may be necessary in severe cases.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic workup includes BMI calculation, waist circumference, fasting lipid profile, HbA1c, and assessment of comorbidities. Imaging (e.g., abdominal ultrasound for gallstones) and specialized tests (e.g., glucose tolerance test) may be required.
Table 414-4: A Guide to Opting for Treatment for Obesity¶
| BMI CATEGORY (kg/m²) | TREATMENT |
|---|---|
| 25–26.9 | Diet, exercise, behavioral therapy |
| 27–29.9 | Diet, exercise, behavioral therapy + pharmacotherapy with comorbidities |
| 30–34.9 | Diet, exercise, behavioral therapy + pharmacotherapy or surgery with comorbidities |
| 35–39.9 | Diet, exercise, behavioral therapy + pharmacotherapy or surgery with comorbidities |
| BMI CATEGORY (kg/m²) | TREATMENT |
|---|---|
| ‡40 | Surgery with comorbidities |
6.1 Laboratory Tests¶
Fasting glucose, lipid panel, HbA1c, liver function tests, and inflammatory markers (e.g., CRP) are essential. Thyroid function tests and cortisol levels help exclude endocrine causes.
6.2 Imaging and Biomarkers¶
Abdominal ultrasound for gallstones, CT for visceral fat assessment, and dual-energy X-ray absorptiometry (DEXA) for body composition analysis may be used.
7. MANAGEMENT & TREATMENT¶
Lifestyle modification is the first-line approach, including dietary changes, physical activity, and behavioral therapy. Pharmacotherapy (e.g., GLP-1 agonists, orlistat) and bariatric surgery are used for severe obesity with comorbidities.
Table 414-5: Antiobesity Medications¶
| DRUG | MECHANISM OF ACTION | ROUTE | PERCENT WEIGHT LOSS (PLACEBO-SU BTRACTED) | COMMON ADVERSE EFFECTS | CONTRAINDIC ATIONS |
|---|---|---|---|---|---|
| Phentermine | Sympathomimeti c, norepinephrine release | Oral | 4.4% | Dry mouth, insomnia, constipation | Uncontrolled hypertension, MAOI use within 14 days |
| Orlistat | Gastrointestinal lipase inhibitor | Oral | 4.1% | Steatorrhea, oily spotting | Chronic malabsorption, calcium oxalate nephrolithiasis |
| Phentermine/To piramate | Sympathomimeti c + GABA modulator | Oral | 8.0% | Nausea, constipation, dizziness | Uncontrolled hypertension, glaucoma |
| Naltrexone/Bupr opion | Opioid antagonist + dopamine reuptake inhibitor | Oral | 5.1% | Nausea, constipation, headache | Medullary thyroid cancer, MEN type 2 |
| Liraglutide | GLP-1 receptor agonist | Subcutaneous | 5.4% | Nausea, diarrhea, constipation | Medullary thyroid cancer, MEN type 2 |
| Semaglutide | GLP-1 receptor agonist | Subcutaneous | 12.5% | Nausea, vomiting, constipation | Medullary thyroid cancer, MEN type 2 |
| Tirzepatide | GLP-1/GIP dual agonist | Subcutaneous | 17.8% | Nausea, vomiting, constipation | Medullary thyroid cancer, MEN type 2 |
7.1 Lifestyle Interventions¶
Caloric restriction (1200–1500 kcal/day), increased physical activity (150 min/week of moderate exercise), and behavioral counseling are recommended. Meal replacements (e.g., shakes, bars) may aid weight loss.
7.2 Pharmacologic Therapy¶
Medications include sympathomimetics (e.g., phentermine), GLP-1 agonists (e.g., liraglutide, semaglutide), and dual agonists (e.g., tirzepatide). Orlistat inhibits fat absorption.
7.3 Bariatric Surgery¶
Laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass are common. Surgery is indicated for BMI ≥ 40 or ≥ 35 with comorbidities. Long-term follow-up is required to monitor complications.
8. PROGNOSIS & COMPLICATIONS¶
Obesity is associated with increased mortality from cardiovascular disease, cancer, and metabolic complications. Long-term weight loss is challenging, with relapse rates high without sustained lifestyle changes. Bariatric surgery improves comorbidities but carries risks of nutritional deficiencies and surgical complications.
8.1 Long-Term Outcomes¶
Weight loss of 5–10% reduces comorbidities, while >10% improves metabolic parameters. However, weight regain is common without behavioral support.
8.2 Complications of Treatment¶
Pharmacotherapy risks include cardiovascular effects (e.g., phentermine), gastrointestinal side effects (e.g., orlistat), and metabolic disturbances (e.g., GLP-1 agonists causing gallstones).
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Obesity increases risks of gestational diabetes and preterm birth. Pediatrics: Childhood obesity requires family-based interventions. Elderly: Weight loss in older adults must balance comorbidities and frailty. Ethnic disparities in BMI thresholds require tailored approaches.
9.1 Pregnancy and Pediatrics¶
Obesity in pregnancy is linked to complications like preeclampsia and macrosomia. In children, early intervention with diet and activity is critical to prevent long-term metabolic risks.
9.2 Elderly Patients¶
Weight loss in older adults must prioritize functional status and avoid malnutrition. Bariatric surgery is less commonly used due to higher surgical risks.
10. KEY POINTS & CLINICAL PEARLS¶
- BMI ≥ 30 defines obesity, but waist circumference is critical for assessing visceral fat risk. 2. Lifestyle modification is the first-line therapy, with pharmacotherapy and surgery reserved for severe cases. 3. GLP-1 agonists (e.g., semaglutide) offer the highest weight loss efficacy. 4. Bariatric surgery improves comorbidities but requires lifelong follow-up. 5. Obesity is a major risk factor for multiple cancers, necessitating early intervention.